// App-Quantinova.ai

: LYMRIT 37-01: A Phase I/II Study of 177lu-Lilotomab Satetraxetan (Betalutin®) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Researchers

Presenter

  • Arne Kolstad

Principal Investigators

  • Matthew Beasley

  • Michael Bayne

  • Tim M. Illidge

  • Noelle O'Rourke

  • Ingemar Lagerlf

  • Roman Hajek

  • Wojciech Jurczak

  • Ella Willenbacher

  • Unn Merete Fagerli

  • Ale Obr

  • Johan Blakkisrud

  • Ayca Muftuler Lndalen

  • Lisa Rojkjaer

  • se stengen

  • Nils Bolstad

  • Signe Spetalen

  • Martin Erlanson

  • Renate Galleberg

  • Stine Nygaard Rud

  • Harald Holte

Medical Centers

  • Department of Oncology, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway

  • Department of Radiology and Nuclear medicine, Oslo University Hospital, National Hospital, Oslo, Norway

  • Bristol Oncology, Bristol, United Kingdom

  • Dorset Cancer Centre Poole, Hampshire, United Kingdom

  • Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • NSGO, University Hospital Linkoeping, Linkoeping, Sweden

  • University Hospital, Ostrava, Czech Republic

  • Malopolskie Medical Center, Krakow, Poland

  • Medical University Innsbruck, Innsbruck, Austria

  • St. Olavs Hospital, Trondheim, Norway

  • Department of Hemato-Oncology, Palacky University Olomouc and the University Hospital Olomouc, Olomouc, Czech Republic

  • Department of Oncology, Oslo University Hospital, Oslo, Norway

  • Nordic Nanovector, Oslo, Norway

  • Department of Oncology, Oslo University Hospital, Oslo, Norway

  • Oslo University Hospital, Oslo, Norway

  • Department of Oncology, Lund University Hospital, Lund, Sweden

  • Department of Oncology, Haukeland University Hospital, Bergen, Norway

Locations

  • Norway

  • United Kingdom

  • Sweden

  • Czech Republic

  • Poland

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

Biomarkers

  • 18F-fluorodeoxyglucose

Drug/Treatment

  • Betalutin

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved